Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 4 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the...
Moderna quarterly sales beat expectations but plummet from previous year
Reuters via AOL· 4 days ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 4 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 4 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 4 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 2 days agoStrengths Robust mRNA Technology Platform: Moderna Inc (NASDAQ:MRNA) has established a strong...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 4 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna Swings to 1Q Loss, But Sees Data on New Vaccine Later in '24
Market Watch· 4 days agoModerna swung to a hefty first-quarter loss but the maker of Covid 19 vaccines forecast some seasonal strength in ...
Why Moderna Stock Blasted 13% Higher Today
Motley Fool via Yahoo Finance· 4 days agoModerna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells...
Moderna, Inc. (NASDAQ:MRNA) Expected to Earn Q3 2025 Earnings of $1.30 Per Share
ETF DAILY NEWS· 12 hours agoModerna, Inc. (NASDAQ:MRNA – Free Report) – Equities research analysts at William Blair lifted their Q3 2025 EPS estimates for Moderna in a report released ...